Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris

 

The general recommendations developed in this guideline are based on the Living Cochrane review (https://pubmed.ncbi.nlm.nih.gov/35603936/). With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations.

 

 

Download entire guideline document in the latest version (September 2023, partial update February 2025): 

Download
10245

Last updated
Changes
Download
Introduction, scoping, population and targeted users
09/2023
Editorial changes
Download
647
Disease severity and treatment goals
09/2023
No changes
Download
1209
Methods and evidence section
02/2025
Editorial changes
Download
324
Main Recommendations and Decision Grid
02/2025
Pregnancy changes were added
Download
1697
Implementation slides
02/2025
New data added
Download
632
IFPA Guideline
09/2023
Editorial changes
Download
651

Last updated
Changes
Download
Acitretin
03/2023
No changes, minor editorial changes in 2025
Download
509
Ciclosporin
03/2023
Reference added
Download
431
Fumarates
03/2023
No changes
Download
188
Methotrexate
03/2023
New data added, pregnancy changes were added in 2025
Download
748
Adalimumab
03/2023
No changes, minor editorial changes in 2025
Download
353
Apremilast
03/2023
New data added
Download
419
Bimekizumab
09/2023
New data added
Download
325
Brodalumab
09/2023
New data added
Download
133
Certolizumab – Pegol
09/2023
No changes, minor editorial changes in 2025
Download
147
Deucravacitinib
02/2025
Recommendation concerning laboratory controls updated
Download
346
Etanercept
03/2023
No changes
Download
105
Guselkumab
03/2023
No changes
Download
279
Infliximab
03/2023
No changes, minor editorial changes in 2025
Download
137
Ixekizumab
09/2023
New data added
Download
217
Risankizumab
09/2023
New data added
Download
384
Secukinumab
09/2023
New data added
Download
239
Tildrakizumab
03/2023
No changes
Download
180
Ustekinumab
03/2023
No changes
Download
186
Biosimilars
09/2023
New data added, minor changes in 2025
Download
150
Newly approved medications and treatments in the pipeline
10/2021
No changes
Download
301

Last updated
Changes
Download
Psoriatic arthritis
03/2023
New data added, recommendations changed
Download
552
Inflammatory bowel disease
10/2021
Recommendation concerning bimekizumab added
Download
223
Cancer
09/2023
New data added, minor changes in 2025
Download
636
Depression
09/2023
New data added, minor editorial changes in 2025
Download
163
Diabetes Mellitus
09/2023
New data added, recommendations changed, minor changes in 2025
Download
249
Heart disease
03/2023
New data added, minor editorial changes in 2025
Download
301
Kidney disease
03/2023
New data added
Download
151
Neurological diseases
09/2023
New data added, minor editorial changes in 2025
Download
177
Viral Hepatitis
02/2025
New data added, recommendations changed
Download
268
Tuberculosis: Screening
09/2023
Editorial changes, minor editorial changes in 2025
Download
254
Tuberculosis: Treatment
09/2023
Editorial changes, minor editorial changes in 2025
Download
265
Wish for child / Pregnancy
02/2025
New data added, recommendations changed
Download
491
Vaccinations
03/2023
Completely new written
Download
324
Inmunogenicity
10/2021
No changes
Download
132

Last updated
Changes
Download
Methods Report
02/2025
Editorial changes
Download
256
Strength and limitations
09/2023
No changes
Download
85
Abbreviations
09/2023
Editorial changes
Download
42